drugset / Trial / NCT07499544
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Timeline
- Start
- 2026-04-22
- Primary completion
- 2028-09-12
- Completion
- 2030-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Libevitug | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Libevitug | Monoclonal antibody | 20 mg/kg | Intravenous |